OpenLB
Open Library of Bioscience
Advanced Search
Pharmaceutics
Jan 01, 2022;14 (1):

Immunogenic Properties of MVs Containing Structural Hantaviral Proteins: An Original Study.

Layaly Shkair, Ekaterina Evgenevna Garanina, Ekaterina Vladimirovna Martynova, Alena Igorevna Kolesnikova, Svetlana Sergeevna Arkhipova, Angelina Andreevna Titova, Albert Anatolevich Rizvanov, Svetlana Francevna Khaiboullina
Author Information
  1. Layaly Shkair: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  2. Ekaterina Evgenevna Garanina: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  3. Ekaterina Vladimirovna Martynova: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  4. Alena Igorevna Kolesnikova: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  5. Svetlana Sergeevna Arkhipova: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  6. Angelina Andreevna Titova: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
  7. Albert Anatolevich Rizvanov: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. ORCID
  8. Svetlana Francevna Khaiboullina: Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
PMID: 35056989 DOI: 10.3390/pharmaceutics14010093

Abstract

Hemorrhagic fever with renal syndrome (HFRS) is an emerging infectious disease that remains a global public health threat. The highest incidence rate is among zoonotic disease cases in Russia. Most cases of HFRS are reported in the Volga region of Russia, which commonly identifies the Puumala virus (PUUV) as a pathogen. HFRS management is especially challenging due to the lack of specific treatments and vaccines. This study aims to develop new approaches for HFRS prevention. Our goal is to test the efficacy of microvesicles (MVs) as PUUV nucleocapsid (N) and glycoproteins (Gn/Gc) delivery vehicles. Our findings show that MVs could deliver the PUUV N and Gn/Gc proteins in vitro. We have also demonstrated that MVs loaded with PUUV proteins could elicit a specific humoral and cellular immune response in vivo. These data suggest that an MV-based vaccine could control HFRS.

Keywords

delivery system hemorrhagic fever with renal syndrome microvesicles orthohantavirus vaccine

References

J Biomed Biotechnol. 2010;2010:641757 [PMID: 20508728]
Cytokine. 1993 Jan;5(1):47-56 [PMID: 8485305]
Oncotarget. 2017 Jul 31;8(41):70496-70507 [PMID: 29050297]
J Virol Methods. 1992 Sep;39(1-2):139-47 [PMID: 1358908]
Adv Mater. 2018 Apr;30(15):e1706616 [PMID: 29473230]
Curr Opin Hematol. 1997 May;4(3):183-90 [PMID: 9209834]
Methods Mol Biol. 2021;2210:157-166 [PMID: 32815136]
Front Immunol. 2014 Oct 07;5:491 [PMID: 25339958]
Cell Mol Immunol. 2019 May;16(5):423-429 [PMID: 30796350]
Vaccine. 2021 May 27;39(23):3152-3160 [PMID: 33934918]
Front Cell Infect Microbiol. 2020 Mar 25;10:102 [PMID: 32269968]
Emerg Infect Dis. 2006 Jan;12(1):166-8 [PMID: 16494739]
Clin Exp Immunol. 2019 Jun;196(3):287-304 [PMID: 30985006]
Nephron Clin Pract. 2009;112(2):c115-20 [PMID: 19390211]
Sci Rep. 2019 Sep 10;9(1):12937 [PMID: 31506515]
Epidemiol Infect. 2016 Feb;144(3):618-26 [PMID: 26160776]
Front Immunol. 2020 Mar 03;11:306 [PMID: 32194558]
Microb Pathog. 2021 Jan;150:104705 [PMID: 33352214]
Sci Rep. 2018 Jan 15;8(1):749 [PMID: 29335595]
Sci Rep. 2017 Jul 13;7(1):5334 [PMID: 28706221]
Vaccine. 2016 Mar 4;34(10):1252-8 [PMID: 26827663]
Mediators Inflamm. 2009;2009:193970 [PMID: 19753321]
Virol J. 2020 Jan 31;17(1):15 [PMID: 32005266]
Biomicrofluidics. 2019 Dec 06;13(6):064124 [PMID: 31832122]
Virology. 1999 Mar 15;255(2):269-78 [PMID: 10069952]
Eur J Clin Microbiol Infect Dis. 2011 May;30(5):645-51 [PMID: 21222012]
Front Immunol. 2020 Feb 14;11:80 [PMID: 32117243]
Infect Dis (Lond). 2016 Apr;48(4):262-266 [PMID: 26654580]
Vaccine. 2014 Feb 3;32(6):740-5 [PMID: 24252696]
Allergy. 2007 Jan;62(1):59-65 [PMID: 17156343]
Nat Commun. 2018 Mar 6;9(1):960 [PMID: 29511190]
Ann Hematol. 1999 Mar;78(3):117-23 [PMID: 10211753]
Hum Vaccin Immunother. 2017 Apr 3;13(4):802-807 [PMID: 27824286]
Cochrane Database Syst Rev. 2003;(3):CD003066 [PMID: 12917944]
Sci Rep. 2020 Jul 1;10(1):10740 [PMID: 32612100]
Curr Gene Ther. 2014;14(3):200-10 [PMID: 24867065]
J Immunol. 2007 Aug 1;179(3):1988-95 [PMID: 17641066]
Cell Mol Immunol. 2021 Oct;18(10):2307-2312 [PMID: 34471260]
Virology. 2004 May 20;323(1):108-19 [PMID: 15165823]
Clin Lab Med. 2010 Mar;30(1):67-91 [PMID: 20513542]
Oncotarget. 2016 Sep 27;7(39):63488-63503 [PMID: 27542281]
Iran J Microbiol. 2019 Jun;11(3):212-219 [PMID: 31523404]
Curr Treat Options Infect Dis. 2020 Oct 29;:1-12 [PMID: 33144850]
Front Cell Infect Microbiol. 2020 Nov 02;10:545372 [PMID: 33251155]
Physiology (Bethesda). 2019 May 1;34(3):169-177 [PMID: 30968753]
J Exp Med. 1988 Mar 1;167(3):1253-8 [PMID: 3127525]
Sci Rep. 2021 Jul 5;11(1):11596 [PMID: 34226582]
Antiviral Res. 2018 Feb;150:174-182 [PMID: 29273568]
Lancet. 1996 May 25;347(9013):1483 [PMID: 8676649]
Ter Arkh. 2003;75(6):28-31 [PMID: 12920955]
Viral Immunol. 2008 Mar;21(1):49-60 [PMID: 18355122]
Cells. 2020 Apr 01;9(4): [PMID: 32244730]
Infect Dis (Lond). 2018 Jan;50(1):21-26 [PMID: 28703073]
J Am Chem Soc. 2005 Mar 9;127(9):2908-12 [PMID: 15740126]
Blood. 1998 Dec 1;92(11):4212-9 [PMID: 9834226]
Adv Drug Deliv Rev. 2018 May;130:12-16 [PMID: 29959959]
J Virol. 1990 Jul;64(7):3162-70 [PMID: 1972201]
J Exp Med. 1997 Feb 3;185(3):461-9 [PMID: 9053446]
Trends Immunol. 2004 Dec;25(12):677-86 [PMID: 15530839]
Vaccine. 2009 Nov 5;27 Suppl 4:D61-4 [PMID: 19837289]
Antivir Ther. 2013;18(4):575-84 [PMID: 23300158]
J Biol Chem. 1996 Mar 29;271(13):7725-30 [PMID: 8631813]
Leukemia. 2020 Dec;34(12):3126-3135 [PMID: 32929129]
J Immunol. 2015 Aug 15;195(4):1341-9 [PMID: 26254266]
Clin Microbiol Rev. 2010 Apr;23(2):412-41 [PMID: 20375360]
Front Microbiol. 2020 Jan 30;10:2989 [PMID: 32082263]
Viruses. 2019 Aug 27;11(9): [PMID: 31461937]
Int J Mol Sci. 2021 Jan 24;22(3): [PMID: 33498909]
Transplant Proc. 2008 Oct;40(8):2649-54 [PMID: 18929828]
J Immunol. 1996 Aug 15;157(4):1350-8 [PMID: 8759714]
Int J Environ Res Public Health. 2021 Aug 11;18(16): [PMID: 34444244]
Front Pharmacol. 2019 Sep 05;10:970 [PMID: 31543819]
Adv Virus Res. 2017;98:83-118 [PMID: 28433053]
J Infect Dis. 2012 Feb 1;205(3):412-21 [PMID: 22147790]
Dev Biol Stand. 1998;92:209-14 [PMID: 9554277]
J Proteomics. 2019 Jul 30;204:103403 [PMID: 31170500]
Virus Res. 2014 Jul 17;187:91-6 [PMID: 24370868]
BMC Public Health. 2013 Apr 26;13:394 [PMID: 23622420]
Viruses. 2019 Jul 02;11(7): [PMID: 31269734]
Expert Opin Ther Targets. 2013 Dec;17(12):1439-60 [PMID: 24090198]
Immunity. 2000 Dec;13(6):805-15 [PMID: 11163196]
Vaccine. 1999 Jun 4;17(20-21):2569-75 [PMID: 10418904]
Clin Dev Immunol. 2013;2013:590190 [PMID: 24489577]
Virol J. 2020 Oct 7;17(1):146 [PMID: 33028368]
mBio. 2019 Jan 8;10(1): [PMID: 30622188]
Front Immunol. 2020 Jan 14;10:3049 [PMID: 31993058]
Front Immunol. 2018 Feb 16;9:276 [PMID: 29503649]
Sustain Prod Consum. 2021 Apr;26:343-359 [PMID: 33072833]
J Exp Med. 1994 Mar 1;179(3):881-7 [PMID: 7509365]
J Exp Med. 1988 Feb 1;167(2):570-81 [PMID: 3279154]
Emerg Infect Dis. 2019 Dec;25(12):2325-2328 [PMID: 31742540]
J Virol Methods. 2010 Nov;169(2):365-74 [PMID: 20709108]
Front Immunol. 2019 Dec 13;10:2759 [PMID: 31921102]
Virology. 1996 Feb 15;216(2):397-406 [PMID: 8607269]
Crit Rev Eukaryot Gene Expr. 2010;20(2):87-103 [PMID: 21133840]
Mol Ther. 2017 Apr 5;25(4):989-1002 [PMID: 28215994]
Eur J Pediatr Surg. 2021 Aug;31(4):326-334 [PMID: 34161984]
Nat Rev Rheumatol. 2017 Jul;13(7):399-409 [PMID: 28615731]
Intervirology. 2002;45(4-6):328-33 [PMID: 12602351]
Infect Immun. 2004 Nov;72(11):6511-8 [PMID: 15501782]
Kidney Res Clin Pract. 2018 Dec;37(4):366-372 [PMID: 30619692]
Clin Vaccine Immunol. 2011 Mar;18(3):483-6 [PMID: 21177912]
J Immunol. 2000 Dec 1;165(11):6429-36 [PMID: 11086082]
J Med Microbiol. 2019 Mar;68(3):480-492 [PMID: 30657443]
Cell Transplant. 2018 Jul;27(7):1126-1139 [PMID: 29947256]
J Exp Med. 2002 Sep 2;196(5):579-88 [PMID: 12208874]
Vaccine. 2005 Jun 10;23(30):3973-83 [PMID: 15917119]
Front Cell Infect Microbiol. 2016 Feb 03;6:1 [PMID: 26870699]
Respir Res. 2001;2(3):150-6 [PMID: 11686879]
Yonsei Med J. 2001 Jun;42(3):278-84 [PMID: 11456392]
Inflamm Res. 2009 Jan;58(1):1-8 [PMID: 19132498]
Biotechnol Adv. 2017 Sep;35(5):565-574 [PMID: 28522212]
Pharmaceutics. 2020 Jun 23;12(6): [PMID: 32585863]
J Intern Med. 2019 May;285(5):510-523 [PMID: 30663801]
Sci Rep. 2016 Apr 22;6:24931 [PMID: 27103188]
ACS Nano. 2017 Jan 24;11(1):69-83 [PMID: 28068069]

Grants

  1. #19-74-00113/Russian Science Foundation
Journal Article

Word Cloud

Similar Articles

Cited By